Search results
Showing 1 to 15 of 42 results for semaglutide
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Evidence-based recommendations on semaglutide (Wegovy) for reducing the risk of major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity in adults.
Show all sections
In development Reference number: GID-TA11920 Expected publication date: TBC
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development Reference number: GID-TA11414 Expected publication date: 10 June 2026
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]
Topic prioritisation
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
We are listening to your views on this Technology appraisal guidance. Comments close 25 June 2026.
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
In development Reference number: GID-TA11477 Expected publication date: TBC
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.